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ABSTRACT
Background
Melanoma patients vaccinated with tumor-associated antigens frequently develop mea-
surable peptide-specific CD8þ T cell responses; however, such responses often do not confer
clinical benefit. Understanding why vaccine-elicited responses are beneficial in some patients
but not in others will be important to improve targeted cancer immunotherapies.
Methods and Findings
We analyzed peptide-specific CD8þ T cell responses in detail, by generating and
characterizing over 200 cytotoxic T lymphocyte clones derived from T cell responses to
heteroclitic peptide vaccination, and compared these responses to endogenous anti-tumor T
cell responses elicited naturally (a heteroclitic peptide is a modification of a native peptide
sequence involving substitution of an amino acid at an anchor residue to enhance the
immunogenicity of the peptide). We found that vaccine-elicited T cells are diverse in T cell
receptor variable chain beta expression and exhibit a different recognition profile for
heteroclitic versus native peptide. In particular, vaccine-elicited T cells respond to native
peptide with predominantly low recognition efficiency—a measure of the sensitivity of a T cell
to different cognate peptide concentrations for stimulation—and, as a result, are inefficient in
tumor lysis. In contrast, endogenous tumor-associated-antigen-specific T cells show a
predominantly high recognition efficiency for native peptide and efficiently lyse tumor targets.
Conclusions
These results suggest that factors that shape the peptide-specific T cell repertoire after
vaccination may be different from those that affect the endogenous response. Furthermore,
our findings suggest that current heteroclitic peptide vaccination protocols drive expansion of
peptide-specific T cells with a diverse range of recognition efficiencies, a significant proportion
of which are unable to respond to melanoma cells. Therefore, it is critical that the recognition
efficiency of vaccine-elicited T cells be measured, with the goal of advancing those modalities
that elicit T cells with the greatest potential of tumor reactivity.
Introduction
The immunotherapy of cancer holds promise in harnessing the host immune response to
speciﬁcally target tumor cells without harming normal tissues. Strategies involve adoptive
cellular therapy or active immune induction (commonly referred to as ‘‘cancer vaccination’’).
Cancer vaccines may consist of whole tumor cells or tumor lysates, but identiﬁcation of tumor-
associated antigens (TAAs) over the past decade has made possible the use of speciﬁc proteins
or peptides as cancer vaccines. The anti-tumor potential of TAA-speciﬁc CD8þT cells has been
illustrated by the demonstrated capacity of adoptive T cell therapy to reduce tumor size [1].
While endogenous anti-tumor CD8þT cell responses may already exist in some cancer patients
[2], vaccination with TAA-derived peptides, and in particular heteroclitic peptide analogs,
increases the frequency of TAA-speciﬁc T cell responses to detectable levels in many patients
[3,4,5,6,7,8,9]. Heteroclitic peptide analogs are created by substitutions at anchor residues
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histocompatibility complex (MHC) [10]. Consequently, heter-
oclitic peptide analogs are predicted to be more immuno-
genic than their native counterparts because of more stable
binding at the surface of antigen-presenting cells (APCs).
Indeed, T cells capable of tumor lysis have been isolated from
patients vaccinated with heteroclitic peptide [8,11,12,13].
However, the presence of TAA-speciﬁc T cells elicited by
vaccination often does not correlate with clinical responses
[3,14,15,16,17].
Various reasons for the paradoxical coexistence of cancer
cells and TAA-speciﬁc T cells within patients have been
proposed [18,19]. One possibility is that elicited TAA-speciﬁc
T cells are not optimally functional in vivo [2,18]. Another
possibility is that T cells inefﬁcient in tumor recognition or
lysis are induced by vaccination [20]. It is becoming
recognized that antigen-speciﬁc T cells may have substantially
different requirements for cognate peptide (the peptide that
is recognizable to a speciﬁc T cell clone) for efﬁcient target
lysis [20,21,22,23]. ‘‘Recognition efﬁciency’’ (RE) (also known
as ‘‘functional avidity’’) is a measure of the sensitivity of a T
cell to different peptide concentrations for stimulation
[24,25,26]. We hypothesized that high antigen densities on
APCs resulting from vaccination with heteroclitic peptide
may paradoxically drive T cells of predominantly low RE,
which are not efﬁciently activated by the endogenous
expression levels of native peptides on tumor cells. Con-
sequently, such T cells would be ineffective in tumor cell
destruction. Support for this notion is emerging: T cells with
low RE are predominantly expanded in vitro with high
peptide concentration [22]. Moreover, in vitro stimulation of
T cells from healthy donors with heteroclitic peptides results
in expansion of cells with a wide range of RE [23]. A similar
phenomenon may occur in vivo, leading to TAA-speciﬁc T
cells of low RE depending on the nature of antigen
stimulation [20].
While isolated T cell clones with low RE have indeed been
generated from melanoma patients following heteroclitic
peptide vaccination, the proportion of vaccine-elicited T cell
responses these cells represent in vivo is not clear. If
predominantly high-RE, tumor-cytolytic T cells are gener-
ated, then a small fraction of low-RE T cells generated would
be of little consequence. However, if predominantly low-RE T
cells are generated, then this low proportion of high-RE T
cells may be an important factor in the observed lack of
clinical effectiveness of current cancer vaccination strategies.
To address this important issue, we undertook a systematic
examination of the complexity of T cell responses induced by
heteroclitic peptide vaccination, and compared these re-
sponses to endogenous anti-tumor T cell responses which
develop in some patients. Typically, responses to vaccination
are examined following in vitro expansion from patient
samples, which may alter the composition of cells and
consequently not reveal the proportion of cells in vivo having
sufﬁciently high RE to lyse tumor targets. Although staining
with peptide–MHC tetramers provides a direct estimate for
the number of TAA-speciﬁc T cells present in vivo, and
intensity of tetramer staining has been employed as a
parameter for isolation of high-RE, tumor-lytic T cells [27],
staining intensity does not correlate well with RE or tumor-
lytic potential [28,29], and cannot be considered a reliable
indicator for the functional status of TAA-speciﬁc T cells.
To analyze and compare T cell responses in melanoma
patients on a single-cell level, we generated and examined a
large number of cytotoxic T lymphocyte (CTL) clones derived
from post-vaccination or endogenous anti-tumor T cell
responses. Each clone was analyzed for T cell receptor
(TCR) variable chain beta (VB) expression, RE, and ability
to lyse melanoma targets. Importantly, these clones were
generated directly ex vivo through tetramer-guided sorting,
which minimizes the selection bias that could be introduced
by prior in vitro expansion. Therefore, data from these clones
could be taken to estimate the complexity of the responses in
vivo.
Methods
Patients and Samples
All patients had resected stage III or IV melanoma, as
determined by the 1988 modiﬁed American Joint Commis-
sion on Cancer staging system. They were required to have a
magnetic resonance imaging or computed tomographic scan
of the head and computed tomographic scans of the chest,
abdomen, and pelvis showing no indication of disease within
4 wk of therapy to verify that they were clinically free of
melanoma. Eligibility criteria included age 18 y or older,
creatinine of less than 180 lmol/l, bilirubin of less than 110
lmol/l, platelet count of 100 3 10
9/l or more, hemoglobin of
90 g/l or more, and total white blood cell count of 3.0 3 10
9/l
or greater. Tests for human immunodeﬁciency virus, hepatitis
C antibody (Ab), and hepatitis B surface antigen were
required to be negative, and all patients were HLA-A2
antigen positive by a microcytotoxicity assay. All patients
were required to comprehend and sign an informed consent
form approved by the National Cancer Institute (NCI;
Bethesda, Maryland, United States) and the Los Angeles
County/University of Southern California Institutional Re-
view Board. Analysis of the patient samples was approved by
Stanford University’s Institutional Review Board. Peripheral
blood mononuclear cell (PBMC) samples were isolated from
patients after vaccination with the heteroclitic peptides
MART 26–35 (27L) (ELAGIGILTV) and gp100 209–217
(210M) (IMDQVPSFV) at the University of Southern Cal-
ifornia Norris Cancer Center (Los Angeles, California, United
States). Clinical-grade peptides used were provided by the
Cancer Therapy Evaluation Program of the NCI under an
Investigational New Drug application BB 6123 held by the
NCI. Immunizations (1 mg of each peptide emulsiﬁed with
incomplete Freund’s adjuvant) were administered every 2 wk
for 8 wk, then every 4 wk for 12 wk, and then once 8 wk later.
PBMC samples were collected 4 wk after the ﬁnal immuniza-
tion and stored at  130 8C. Samples were thawed the day
before an experiment for overnight culture in CTL medium.
The following morning, viable cells were isolated by ﬁcoll
density centrifugation, washed, and resuspended to the
appropriate concentration in a solution of 90% Iscove’s
Modiﬁed Dulbecco’s Medium (IMDM) and 10% fetal bovine
serum (FBS).
Flow Cytometry Analysis
For isolation and detection of peptide-speciﬁc T cells,
patient PBMC samples were stained and analyzed by
ﬂuorescence-activated cell sorting (FACS) as previously
described [2]. Brieﬂy, cells were stained with anti-human
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lingame, California, United States) and CD19-CyChrome (BD
Biosciences, Palo Alto, California, United States) Abs, and
HLA-A*0201/peptide tetramer–phycoerythrin (PE). The ﬁnal
staining dilution of each Ab was 1/200 and 1/80, respectively.
Tetramer–PE was titrated for optimal staining, usually
between 1 and 10 lg/ml. For TCR VB typing, cells were
divided in seven aliquots and stained with CD8 PerCP-Cy5.5
(BD Biosciences), tetramer–PE, and a panel of two or three
different anti-VB monoclonal Abs labeled with ﬂuorescein
isothiocyanate, allophycocyanin (APC), or both. Cells were
incubated at room temperature for 30 min, washed, then
analyzed using a two-laser, four-color FACSCalibur (Becton
Dickinson, Franklin Lakes, New Jersey, United States) or
sorted using a FACSVantage ﬂow cytometer (Becton Dick-
inson). Lymphocytes were identiﬁed by forward and side
scatter signals, then selected for CD8þand tetramer positive.
Up to one million events were acquired and analyzed using
FlowJo (TreeStar, San Carlos, California, United States).
CD107 Mobilization Assays
Target cells. The HLA-A*0201-positive melanoma lines
Malme-3M and A375 and the T2 cell line were purchased
from ATCC (Manassas, Virginia, United States) and main-
tained according to instructions provided by the ATCC. The
HLA-A*0201-positive melanoma line mel526 was obtained
from the Surgery Branch of the NCI. While Malme-3M and
mel526 express both MART and gp100, A375 does not
express MART or gp100 and served as a negative control.
Expression (or lack thereof) of these antigens by each cell line
was further conﬁrmed by immunohistochemical staining.
Cells were trypsinized using Trypsin/EDTA solution (GIBCO,
San Diego, California, United States) before use. T2 cells were
HLA-A2.1þ and were pulsed prior to assays with peptides
indicated in the text.
Effector cells. Effector cells, which include clones, cell line,
and PBMC samples, were frozen and analyzed in batches. The
cells were thawed the day before an experiment for overnight
culture in CTL medium. The following morning, viable cells
were isolated by ﬁcoll density centrifugation, washed, and
resuspended to theappropriate concentration (usually 10
7/ml)
in CTL medium.
Experimental procedure. All assays were done at least
twice, with duplicates for each condition. The effector to
target (E:T) ratio used was generally 1:2, with 2 3 10
5 for
clones or 10
6 for the cell line and patient PBMC samples. To
each well, the following was added in order: 1 llo f2m M
monensin (Sigma, St. Louis, Missouri, United States) in 100%
EtOH, 100 ll of target cells, 100 ll of effector cells, and 1 llo f
CD107-APC Abs. The cells were mixed well using a multi-
channel pippetor. The plate was centrifuged at 300g for 1 min
to pellet cells, then placed into an incubator at 37 8C for 4 h.
After the incubation, the plates were centrifuged to 500g to
pellet cells, and the supernatant was removed. Cell–cell
conjugates were disrupted by washing the cells with PBS
supplemented with 0.02% azide and 0.5 mM EDTA, and
mixed vigorously, then stained with additional Abs.
Generation of CTL Clones
CD8þ T cell clones were derived by FACSorting individual
tetramer-positive cells from PBMC samples prepared for ﬂow
cytometry as described above. CD8þtetramer-positive T cells
were sorted under sterile conditions into 96-well plates, one
cell per well, using a FACS Vantage (Becton Dickinson). Wells
contained 100 ll of CTL IMDM, with 10% FBS, 2% human
AB sera, and penicillin, streptomycin, and L-glutamine,
supplemented with 100 units/ml IL-2. Sorted cells were
expanded in vitro using standard protocols. Brieﬂy, irradi-
ated feeder cells (JY cells and fresh PBMCs) were added to
wells containing the sorted T cells, and the 96-well plates were
incubated at 37 8C with 7% CO2 to allow for growth. Potential
clones became visible around day 14 and were then trans-
ferred to 24-well plates containing 1 ml of CTL medium with
100 units/ml IL-2. Wells were selected based on cell
conﬂuency for expansion and further analysis. Clones
conﬁrmed to be tetramer-positive were expanded in T-25
ﬂasks containing irradiated JY cells and fresh PBMCs in 25 ml
of CTL medium containing PHA. IL-2 was added to a ﬁnal
concentration of 50 units/ml on day 1 and then every 2 d
thereafter for 2 wk.
Cytotoxic Assays
Target cells. Target cells were as described above under
CD107 Mobilization Assays, and were labeled overnight with
51Chromium, washed, and resuspended to 10
5 cells/ml. One
hundred microliters of target cells were incubated with 100 ll
CTL clones at 10:1 E:T ratio for 4 h. Percent speciﬁc release
of
51Chromium from target cells was calculated from 40-ll
cell-free supernatants.
Determination of RE. Chromium-labeled T2 targets were
pulsed with a range of peptide concentrations, generally
starting at 10
 7 M and decreasing by log steps to 10
 13 M. T
cell clones were incubated with T2 targets at 10:1 E:T ratios
for 4 h, then chromium release was measured and percentage
cytotoxicity calculated by standard methods. Prior to each
cytotoxicity assay, clones underwent ﬁcoll-hypaque centrifu-
gation to remove dead feeder cells and were determined to be
greater than 80% CD8þ tetramer-positive T cells by FACS.
The E:T ratio was based upon live T and target cells. For each
T cell clone, percent cytotoxicity was plotted against peptide
concentration. The peptide concentration at which the curve
crossed 40% cytotoxicity was deﬁned as the RE of that clone
[30].
Microcytotoxic assay. Cells were isolated directly from
PBMCs from patient 422 by FACS as described above. Cells
were collected in microfuge tubes containing 1 ml of ice-cold
90% IMDM with 10% FBS. Collected cells were washed and
resuspended to 83,300 cells/ml in 90% IMDM with 10% FBS.
Targets were prepared as described above and resuspended
to 8,300 cells/ml in 90% IMDM with 10% FBS. A total of 2,500
sorted cells (30 ll) and 250 target cells (30 ll) were transferred
to a microcentrifuge tube (VWR International, West Chester,
Pennsylvania, United States), centrifuged 1 min at 200g, and
i n c u b a t e d4ha t3 78C. Percent speciﬁc release of
51Chromium was calculated from 40 ll of cell-free super-
natant.
TCR VB Spectratyping
RNA was extracted from clones and tetramer-positive cells
using TRIzol (Invitrogen, Carlsbad, California, United States)
and reverse-transcribed into cDNA using SuperScript II
Reverse Transcriptase (Invitrogen). PCR was performed using
34 different 59 primers that speciﬁcally amplify all functional
TCR VB genes. Most of the 59 primers used have been
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combination with a common 39 primer based in the beta
chain constant region, BC63 (59-GTGTGGCCTTTTGGGTGT-
39). As an internal control, PCR for a section of the beta chain
constant region was performed in parallel with VB-speciﬁc
PCRs using the following primers: UpBC (59-
CGCTGTGTTTGAGCCATC-39) and LoBC (59-TGCTCAGG-
CAGTATCTGGA-39). All primer concentrations were 200
nM. PCR was performed using an iCycler iQ thermic cycler
equipped with a real-time detection system (Bio-Rad,
Hercules, California, United States) and a QuantiTect SYBR
Green PCR kit (Qiagen, Valencia, California, United States).
PCR reactions were performed as follows: 94 8C for 9 min,
followed by 50 cycles of 94 8C for 30 s, 58 8C for 1 min, and 72
8C for 1 min, followed by 72 8C for 10 min. Speciﬁc
ampliﬁcation was determined relative to constant region
control PCR. For spectratyping, PCRs were performed as
described above with the following VB14- and VB17-speciﬁc
59 primers: VB14m (59-ACCCAAGATACCTCATCACAG-39)
and VB17 (59-GACAGGACCCAGGGCAAG-39), followed by a
run-off PCR with downstream VB-speciﬁc primers: VB14 (59-
GGGCTTAAGGCAGATCTACT-39) and VB17m (59-TTTCA-
GAAAGGAGATATAGCT-39), and FAM6-labeled BC63 39
primer. Run-off PCR was performed as described above
except that only ﬁve cycles of PCR were run with the 55 8C
annealing temperature and QuantiTect Probe PCR kit
(Qiagen). Labeled PCR fragments were run on an ABI Prism
377 DNA Sequencer (Applied Biosystems, Foster City,
California, United States) and analyzed using GeneScan
software (Applied Biosystems).
Statistical Analysis
A standard software package (SigmaPlot 5.0, Systat Soft-
ware, Richmond, California, United States) was used to
provide descriptive statistical plots. Barcharts were provided
with standard errors on them. Linear plots were provided
with standard errors computed at each point. A linear
regression (using least squares) of percent speciﬁc lysis on
recognition efﬁciency is shown in Figure 5A and 5B.
Results
T Cell Responses to TAAs in Patients with Melanoma
To address the complexity of T cell responses against
melanoma in vivo, patients with vaccine-induced or endog-
enous TAA-speciﬁc responses were selected. In recent cancer
vaccine trials [3,4,5], many melanoma patients who received
heteroclitic peptide vaccines gp100 209–217 (210M)
(IMDQVPSFV; G209–2M) and MART 26–35 (27L) (ELAGI-
GILTV; M26) had measurable CD8þ peptide-speciﬁc T cell
responses in PBMCs detected by peptide–MHC tetramer
staining. In addition, TAA-speciﬁc T cell responses could be
detected in some patients without vaccination, suggesting the
existence of an endogenous anti-tumor T cell response in
these patients. For the current study, we selected samples
from six melanoma patients from these trials—four with
vaccine-elicited responses (patients 422, 476, 517, and 520)
and two with endogenous T cell responses (patients 132 and
Figure 1. Melanoma Patient Samples Selected for Analysis of RE for Melanoma Cells
(A) Six patients with T cell responses reactive with for M26 or G209–2M tetramers were selected for analysis. PBMCs from each patient were
stained with PE-conjugated peptide–MHC tetramers, G209–2M-tet PE or M26-tet PE, and co-stained with anti-CD8 ﬂuorescein isothiocyanate
and anti-CD14, -CD19, and -CD4 Cy5PE. The plots shown are gated for CD8þ, CD14 , CD19 , and CD4 cells. Tetramer-positive cells are boxed
and estimated for percent of total CD8þcells: patient 422, 2.5%; patient 476, 0.31%; patient 132, 0.22%; patient 517, 0.23%; patient 520, 0.12%,
and patient 461, 0.50%.
(B) Microcytotoxicity
51Chromium release assay with tetramer-positive cells isolated by FACS from the CD8þ PBMC population from patient
422. Isolated cells were assayed for lysis of T2 cells treated with relevant or irrelevant peptide, or mel526 melanoma cells. Sorted cells were
combined with 250 target cells at 13:1 E:T ratios for 4 h, and supernatants were assayed for percent speciﬁc release of radiolabel.
DOI: 10.1371/journal.pmed.0010028.g001
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Patient ID TAA T2/Peptide Percent Tetramer-Positive Percent Functional Response
mel526 Malme-3M A375
422 G209–2M 98.2 – 27.2 23.8 0.5
476 G209–2M 99.6 – 32.5 27.8 2.6
132 G209–2M 99.2 – 87 82.2 2.7
517 M26 86 – 29.3 28.3 6.4
520 M26 93 – 28.5 25.1 2.8
461 M26 95.3 – 54.9 36.8 3
713 M26 – 0.49 18.2 13 6.1
721 M26 – 0.19 49.6 45.2 4.8
721 G209–2M – 0.23 20.8 24.9 5.2
735 M26 – 0.21 30.6 42.1 1.8
735 G209–2M – 2.7 32.6 35 3
722 G209–2M – 0.19 37.4 21.5 6.1
Functional response was determined by percent of G209–2M- and M26-tetramer-positive cells that mobilized CD107 and/or downregulated CD3 complex in response to
incubation with T2 cells pulsed with 100 ng/ml of cognate peptide (G209–2M or M26), mel526, or Malme-3M melanoma cells. A375 melanoma cells served as negative
control.
DOI: 10.1371/journal.pmed.0010028.t001
Table 2. CTL Clones Established from Each Patient Represent a Random Selection from the Tetramer-Reactive CD8þParent Population
TCR
VB
Family
Patient 422
a Patient 476 Patient 132 Patient 520 Patient 517 Patient 461
CTL
b
Clones
Tetramer-
Positive
c
PBMC
CTL
Clones
Tetramer-
Positive
PBMC
CTL
Clones
Tetramer-
Positive
PBMC
CTL
Clones
Tetramer-
Positive
PBMC
CTL
Clones
Tetramer-
Positive
PBMC
CTL
Clones
Tetramer-
Positive
PBMC
VB1 3 1 1% 1 1 8% 7%
VB2 1 3% 1 5%
VB3 2 3% 2 10 1 3 16%
VB5.1 1 5%
VB5.2 1
VB5.4 1
VB6.1 1
VB6.3 1
VB7 25 % 3 %
VB7.2 4
VB8 7 5% 1 4% 4 4% 1
VB9 1
VB12 2 2% 5%
VB12.3 1 1
VB13.1 1 2% 4% 5 11% 14% 2%
VB13.6 1% 7% 7%
VB14 6 17% 44 24% 8 9% 1 8% 4 13%
VB16 1 1% 2%
VB17 7 11% 33 37% 10 86% 8 4% 1 6% 3%
VB20 1 1% 5%
VB21.3 12 4% 2 2%
VB22 1 3%
VB23 1 2 3%
VB24 1 2
VB not
known
122
Total: 49 46% 85 72% 11 87% 47 32% 9 66% 10 61%
aClonal CTL lines were established from each patient.
bNumber of clonal CTL lines from each patient expressing the same TCR VB chain.
cPercent of G209–2M- and M26-tetramer-reactive CD8þ T cells in each patient expressing the indicated TCR VB chain.
DOI: 10.1371/journal.pmed.0010028.t002
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T Cell Responses to CancerTable 3. PCR-Generated Fragment Length Analysis
Clone TCR VB Fragment Length Sorted Cells TCR VB Fragment Length
476.101 VB14 299 476-tetramer-positive VB14 299
476.102 VB14 299
476.105 VB14 299
476.108 VB14 299
476.104 VB17 263 476-tetramer-positive VB17 263
476.125 VB17 263
476.139 VB17 263
476.140 VB17 263
132.1 VB17 266 132-tetramer-positive VB17 266
132.2 VB17 266
132.3 VB17 266
132.4 VB17 266
132.5 VB17 266
132.9 VB17 266
132.10 VB17 266
132.11 VB17 266
PCR fragment length was determined for selected clones and for sorted G209–2M- or M26-tetramer-positive populations from which the clones were derived. Numbers
indicate length in base-pairs of fragments generated by PCR with VB14 or VB17 59 primer and BC63 constant region 39 primer followed by a run-off reaction with VB-specific
nested primers and FAM-labeled BC63 primer. Fragments were analyzed using an Applied Biosystems 377 automated sequencer and GeneScan software.
DOI: 10.1371/journal.pmed.0010028.t003
Table 4. CTL Clones from Each Patient Selected for Functional Analysis
Patient 422 Patient 476 Patient 132 Patient 520 Patient 517 Patient 461
Clone TCR
VB
Assay Clone TCR
VB
Assay Clone TCR
VB
Assay Clone TCR
VB
Assay Clone TCR
VB
Assay Clone TCR
VB
Assay
2A12 VB5.1 MR 476.101 VB14 MR 132.1 VB17 MR 520.17 VB14 MR 517.1 VB7 M 461.4 VB2 MR
2C1 VB14 M 476.102 VB14 M 132.2 VB17 MR 520.21 VB14 MR 517.2 VB5.2 MR 461.8 VB3 MR
2E1 VB7.2 MR 476.105 VB14 MR 132.3 VB17 M 520.20 VB3 MR 517.3 VB1 MR 461.9 VB14 MR
3H3.1 VB20 MR 476.108 VB14 MR 132.4 VB17 M 520.24 VB3 MR 517.7 VB7 MR 461.10 VB3 MR
4A6 VB9 MR 476.133 VB14 M 132.5 VB17 M 520.30 VB17 MR 517.11 VB14 MR 461.17 VB14 MR
4F1 VB1 MR 476.104 VB17 MR 132.6 VB1 MR 520.32 VB17 MR 517.13 VB3 MR 461.21 VB? MR
5F9 VB8 MR 476.125 VB17 MR 132.9 VB17 M 520.22 VB6.1 MR 517.14 VB8 MR 461.24 VB14 MR
1A12 VB21.3 M 476.137 VB17 M 132.10 VB17 M 520.31 VB? MR 517.16 VB5.4 MR 461.25 VB14 MR
422.T1 VB13.1 MR 476.139 VB17 M 132.11 VB17 M 520.33 VB24 MR 517.40 VB17 MR 461.29 VB? MR
422.23 VB14 M 476.140 VB17 M 520.38 VB12.3 MR 461.30 VB3 MR
422.50 VB14 MR 476.15 VB21.3 MR 520.41 VB24 MR
422.47 VB17 MR 476.110 VB3 MR 520.55 VB? MR
422.66 VB17 M 476.N11 VB3 M 520.16 VB8 MR
422.27 VB12 MR 476.25 VB8 MR 520.18 VB16 MR
422.49 VB3 MR 476.N8 VB6.3 MR 520.19 VB13.1 MR
3F2 VB7.2 MR 476.28 VB24 MR 520.43 VB2 MR
2H9 VB12.3 MR 476.114 VB? MR 520.49 VB23 MR
4E2 VB7.2 MR 476.26 VB21.3 M 520.52 VB1 MR
3H3.2 VB7.2 MR 520.59 VB22 MR
422.64 VB8 M
422.72 VB3 M
422.T8 VB1 M
The TCR VB usage of each CTL clone was determined using a panel of 19 anti-VB monoclonal Abs by flow cytometry or by PCR with 34 VB-specific primers. All clones selected
for functional analysis were assayed for lysis of melanoma cells. Some clones were also subjected to RE analysis.
M, assay for lysis of melanoma cells; MR, RE analysis.
DOI: 10.1371/journal.pmed.0010028.t004
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target peptide, and tumor cytotoxicity. The samples from
these six patient had peptide-speciﬁc T cell populations
detectable with G209–2M-tetramers (patients 422, 476, and
132) or M26-tetramers (patients 517, 520, and 461) ranging
from 0.1% to 2.5% of total CD8þ T cells (Figure 1A).
Vaccine-Elicited T Cells Are Functional Directly Ex Vivo but
of Variable Tumor Reactivity
Patient 422 had the largest detectable TAA-speciﬁc CD8þT
cell response (2.5% G209–2M-tetramer-positive) and thus
sufﬁcient numbers for examination of lytic function imme-
diately following isolation. To test whether peptide-vaccine-
induced T cell responses were functionally active directly ex
vivo, T cells isolated by G209–2M-tetramer-guided cell
sorting from patient 422 were tested for lysis of peptide-
pulsed and melanoma target cells in microcytotoxic assays
(Figure 1B). The directly isolated tetramer-positive T cells
from this patient speciﬁcally lysed T2 cells pulsed with high
concentrations (1 lg/ml) of G209–2M and native (G209n)
peptides, but not with T2 cells pulsed with a cytomegalovirus-
derived, HLA-A*0201-restricted peptide (NLVPMVATV) or
melanoma targets. This suggests that while a signiﬁcant
portion of the vaccine-elicited T cells from patient 422 may
be functional in vivo, they did not have signiﬁcant tumor lysis
activity.
To assess the functional status of the smaller TAA-speciﬁc
CD8þT cell responses in the other ﬁve patients—which were
too small for direct cytotoxicity assays after sorting—we
utilized a novel FACS assay for degranulation based on
Figure 2. Endogenous T Cell Responses Are More Efficient in Melanoma Lysis Than Vaccine-Elicited Responses
Cells from 87 clonal CTL lines were assayed for lysis of melanoma cells mel526, Malme-3M, and A375 in
51Chromium release cytotoxicity assays.
Mel526 and Malme-3M are HLA-A2.1þ and express both gp100 and MART-1. A375 cells are HLA-A2.1þ but do not express either gp100 or
MART-1 and served as a negative control. T2 cells treated with 1 lg/ml G209–2M or M26 peptides served as controls for antigen-speciﬁc lysis.
The CTL clones assayed were selected to represent different tetramer-positive subsets expressing different VB. Dominating tetramer-positive
populations in each patient were represented with two or more clones. Each CTL clone was assayed in triplicate wells, and the data displayed are
averages of two different experiments. Clones from the same patient expressing similar VB while exhibiting different lysis potential were viewed
as separate subsets. Each assay was performed at 10:1 E:T ratio as detailed in Methods. The height of each bar represents percent speciﬁc lysis,
while the width represents the relative size of the tetramer-positive subpopulations (deﬁned by VB expression) in each patient. Population size
was deﬁned as the percent of clones from each patient expressing the same VB. Error bars show standard deviation between two experiments
within each clone and/or between different clones where more than one clone was analyzed.
DOI: 10.1371/journal.pmed.0010028.g002
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T Cell Responses to CancerCD107 mobilization [24]. All six TAA-speciﬁc populations
exhibited robust functional responses ex vivo, as measured by
percentage of G2090–2M- and M26-tetramer-positive cells
that mobilized CD107 and/or downregulated the CD3 com-
plex upon incubation with T2 cells pulsed with cognate
peptides (Table 1; 86%-99.6%). In response to melanoma
targets mel526 and Malme-3M, which both express gp100 and
MART-1 and are HLA-A*0201 positive, the two endogenous
TAA-speciﬁc responses (samples from patients 132 and 461)
also exhibited robust functional responses directly ex vivo
(Table 1; 36.8%–87%), and these responses were speciﬁc as
they had little response to A375, a HLA-A*0201-positive
melanoma cell that does not express gp100 or MART-1 and
served as a negative control for antigen-speciﬁc killing (Table
1; 2.7% and 3%). In contrast, the vaccine-elicited responses
exhibited much lower reactivity to mel526 and Malme-3M
(Table 1; 23.8%–32.5%). These data demonstrate that all six
TAA-speciﬁc CD8þ T cell responses were functional ex vivo,
but there were signiﬁcant differences in reactivity to
melanoma targets between endogenous and vaccine-elicited
responses.
To substantiate the generality of these ﬁndings, we
analyzed four additional patients with vaccine-elicited re-
sponses. One subject responded to G209–2M only (patient
722), one to M26 only (patient 713), and two to both G209–2M
and M26 (patients 721 and 735). Similar to the ﬁrst four
vaccine-elicited patients, these four additional patients (six
TAA-speciﬁc responses in total) exhibited variable reactivity
to melanoma targets, ranging from 13% to 49.6% (Table 1).
Vaccine-Elicited T Cells Have Varied Capacity to Lyse
Melanoma Targets
To conﬁrm and further investigate the differences in
tumor reactivity between endogenous and vaccine-elicited
responses, we reasoned that analysis of a set of clonal CTL
lines that represented the tetramer-positive population
would provide an accurate estimate of the complexity of
the TAA-speciﬁc T cell response in each patient. A large
number of clonal CTL lines (more than 200) were generated
by FACS of individual G209–2M- and M26-tetramer-positive
cells directly from PBMC samples (Table 2). Up to 85% of
sorted cells expanded in various sorts (data not shown).
Randomly selected expanding clones and the tetramer-
positive population from which they were derived were
examined for TCR VB expression using TCR VB-speciﬁc
monoclonal Abs and VB-speciﬁc primers in PCR. Diverse
TAA-speciﬁc T cell responses were found in the four
vaccinated patients, with multiple T cells expressing different
TCR VB, while the two endogenous responses were less
diverse. All but one clone derived from patient 132 expressed
VB17, while two dominating T cell populations in patient 476
expressed VB14 and VB17 (Table 2). The clonality of the
dominant populations in these patients was evaluated by PCR
fragment length analysis (Table 3). Identical length fragments
were demonstrated in the four selected clones from 476
BV14þ and 476 BV17þ populations. Identical length frag-
ments were also demonstrated in all BV17þ clones from
patient 132. Furthermore, analysis of sorted tetramer-positive
cells from patient 476 demonstrated single fragment sizes for
BV14 and BV17, which were identical to the fragment sizes
generated from the selected clones, arguing for clonality of
these dominant populations (Table 3).
Peptide speciﬁcity and CD8 expression of each clone was
conﬁrmed by staining with G209–2M- and M26-tetramers and
anti-CD8 monoclonal Ab (data not shown). To obtain an
accurate reﬂection of the total T cell population detected
with tetramer in each patient, we decided to rigorously
examine at least one representative clone for each subpopu-
lation expressing a different TCR VB (Table 4). Multiple
clones were analyzed to determine dominating populations.
From patients 132, 517, and 461, for which fewer clones were
generated, all clones were included in the analyses (Table 4).
To determine the effectiveness of tumor lysis by the
different TAA-speciﬁc T cell clones that were propagated,
clones were analyzed for their ability to lyse melanoma cell
lines mel526 and Malme-3M. A375 cells served as a control for
antigen-speciﬁc killing. In addition, each CTL clone was
examined for antigen-speciﬁc lysis of T2 cells pulsed with
high levels (1lg/ml) of G209–2M or M26 peptides. ‘‘Efﬁcient
lysis’’ in these experiments was deﬁned as 40% or greater
speciﬁc release of radiolabel from the target cells; 10% or less
speciﬁc release was categorized as ‘‘low or no lysis,’’ and 10%
to 40% was termed ‘‘intermediate lysis.’’ All but two of the
CTL clones elicited from endogenous anti-tumor responses
(from patients 132 and 461) exhibited ‘‘efﬁcient lysis’’ of both
the mel526 and Malme-3M melanoma cell lines (Figure 2). In
contrast, only a few clones from the vaccine-elicited
Figure 3. Most CTL Clones Isolated from Endogenous Responses Are
Efficient in Tumor Cell Lysis
CTL clones derived from each patient were classiﬁed as ‘‘efﬁcient’’
(greater than 40%), ‘‘intermediate’’ (between 10% and 40%), or ‘‘low/
no’’ (less than 10%) in lysis of melanoma cells based on data displayed
in Figure 2. Each bar represents the portion of total clones from each
patient with ‘‘efﬁcient,’’ ‘‘intermediate,’’ or ‘‘low/no’’ melanoma lysis
potential.
DOI: 10.1371/journal.pmed.0010028.g003
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lysed melanoma cells. The majority of clones examined from
these vaccine-elicited responses either failed to lyse melano-
ma targets altogether or lysed them with intermediate
efﬁciency (Figure 2). This lack of efﬁciency in melanoma cell
lysis was not due to cellular dysfunction, since each clone
efﬁciently lysed T2 cells pulsed with high levels of relevant,
but not irrelevant, peptide (Figure 2). Overall, the majority of
clones derived from endogenous anti-tumor responses
(patients 132 and 461) lysed both mel526 and Malme-3M
melanoma target cells more efﬁciently than clones from
vaccine-elicited responses (patients 422, 476, 520, and 517)
(Figure 3). These ﬁndings suggest that TAA-speciﬁc T cells
elicited by heteroclitic peptide vaccination have different
tumor-cytolytic potentials from those which develop endo-
genously to cancer.
RE for Native and Heteroclitic Peptides of T Cells from
Endogenous or Vaccine-Elicited Responses
We hypothesized that CTL clones that did not efﬁciently
lyse melanoma targets may be incapable of recognizing the
relatively low surface densities of native peptide present on
tumor cells. CTL clones selected for analysis of tumor lysis
were also assessed for RE for the native and heteroclitic
peptides via a ten-log range of dilutions. This is illustrated
with clones 132.1 and 476.105 (Figure 4A). There were
considerable differences in killing of peptide-pulsed T2 cells
by these two clones. The differences in RE for G209n native
peptide displayed by the two clones highlighted in Figure 3A
correlated with their ability to lyse melanoma cells: the high-
RE clone 132.1 efﬁciently lysed melanoma targets, whereas
the low-RE clone 476.105 did not (Figure 4B). In contrast to
the differences in RE for G209n peptide, similar assays
revealed little difference in RE of the two clones for G209–2M
heteroclitic peptide (Figure 4C), suggesting that these clones
recognize the native and heteroclitic peptides differently, and
that RE for the native, but not heteroclitic, peptide correlates
with tumor-lytic potential.
Similar RE assays were performed for the remaining clones
from each patient selected for analysis. In order to compare
REs of various CTL lines, each clone was assigned an RE score
expressed as the negative log10 value of the peptide
concentration required for 40% speciﬁc lysis at an E:T ratio
of 10:1. For clones 132.1 and 476.105, these scores were 11.1
and 8.3 for assays with G209n peptide (Figure 4A), and 11.2
and 11.2 for assays with G209–2M heteroclitic peptide (Figure
4C), respectively. We compiled the data on clones from all
patients, which showed a correlation between tumor-lytic
potential and RE for native peptide (Figure 5A and 5B).
Overall, clones generated from endogenous anti-tumor
responses had higher RE for the native peptide than clones
generated from post-vaccine responses (Figure 5C and 5D).
We estimated the composite RE of the overall TAA-speciﬁc
response (composed of a heterogeneous population of T cells)
in vivo by summing the RE of each clone multiplied by its
representation in the original mixture (the representation
was estimated based on the proportion of TAA-speciﬁc cells
expressing the same VB as the clone). These composite RE
values are represented in Figure 5 as horizontal bars for each
response. Clearly, the endogenous responses (patients 461
and 132) had a higher overall, and more homogeneous, RE for
the native peptide than the vaccine-elicited responses
(patients 422, 476, 517, and 520) (Figure 5C and 5D).
Importantly, the vaccine-elicited clones also exhibited wide
variations in RE even for the heteroclitic peptide, compared
to the endogenous responses (Figure 5E and 5F). This suggests
Figure 4. High RE Recognition of Native G209n but Not G209–2M
Peptide Correlates with Efficiency in Tumor Cell Lysis
CTL clones 476.105 and 132.1 were assayed for lysis of T2 cells pulsed
with 10-fold dilutions of (A) native or (C) heteroclitc peptide at
concentrations ranging from 100 fg/ml to 100 ng/ml. (B) Lysis of
Malme-3M melanoma cells by 476.105 and 132.1 CTLs. All assays were
performed in triplicate, and each clone was assayed twice. Error bars
reﬂect variation between two separate assays.
DOI: 10.1371/journal.pmed.0010028.g004
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to lyse tumor cells, for vaccine-elicited responses is not
merely a reﬂection of differential recognition of native and
heteroclitic peptides by many clones. Rather, variations in RE
may be a function of the manner in which these cells were
elicited in vivo via vaccination.
Discussion
To achieve maximal clinical responses, the majority of T
cells elicited by vaccination in cancer patients should be
capable of responding to tumor targets. We have undertaken
the most detailed analysis to date, on a single-cell level, of T
cell responses elicited by cancer vaccination and have
compared these with endogenous anti-tumor responses. To
evaluate the full spectrum of T cells elicited in each patient by
vaccination, we utilized tetramers made with the vaccine
peptides (heteroclitic M26 and G209–2M) to isolate such cells.
CTL clones were selected directly from patient PBMC
samples without enrichment in culture to closely reﬂect the
composition of the antigen-speciﬁc T cell response in vivo at
the time of isolation.
Our data revealed that T cell populations induced by
vaccination were signiﬁcantly different from endogenous
responses: while some CTLs elicited by vaccination could kill
melanoma targets, most were inefﬁcient in tumor cell lysis. In
contrast, nearly all clones from endogenous responses were
efﬁcient at melanoma cell lysis. This difference was related to
RE for the native peptide. Clones that did not lyse tumor cells
required up to 10
3-fold higher concentration of peptide for
similar levels of lysis of targets compared to T cell clones that
were tumor-lytic. Side-by-side comparison of endogenous
responses and vaccine-induced responses suggests that low
RE TAA-speciﬁc T cell responses may be preferentially driven
by heteroclitic peptide vaccination. Thus, high doses of
peptide and/or the higher levels of expression of heteroclitic
peptide on APCs may induce and actively propagate
predominantly T cells with RE too low for recognition of
physiological levels of the native peptide present on tumor
targets. These data suggest an inverse relationship between
Figure 5. Endogenous T-Cell Responses Have Higher RE Than Vaccine-Elicited Responses
CTL clones representing different tetramer-positive populations in each patient expressing different VB were assayed for lysis of T2 cells pulsed
with various dilutions of G209n, G209–2M, M27, or M26 peptides in
51Chromium release cytotoxicity assays as described in Figure 4 legend. A RE
score was attributed to each clone equal to the negative log10 of the peptide concentration that resulted in 40% lysis of peptide-pulsed T2 cells.
(A and B) RE scores for both (A) MART-speciﬁc and (B) gp100-speciﬁc clones from all patients were correlated with efﬁciency in lysing
melanoma cells. Correlation coefﬁcients were 0.66 for MART-speciﬁc clones and 0.81 for gp100-speciﬁc clones.
(C–F) Comparison of RE scores for endogenous (patients 461 and 132) and vaccine-induced (patients 517, 520, 422 and 476) responses.
(C and D) RE analysis with native peptides (C) M27 and (D) G209n. Mean RE (weighted) for each response is indicated with horizontal bars.
Weighted means were based on all clones, not only those assayed, and were estimated by summing the RE of each analyzed clone multiplied by
the number of total clones expressing the same VB, in each patient. Weighted means were as follows: patient 517, 5.7; patient 520, 7.0; patient
461, 7.9; patient 422, 9.7; patient 476, 9.9; and patient 132, 11.2. One-tailed T-tests demonstrated that endogenous responses had signiﬁcantly
higher RE than vaccine-induced responses: patient 461 versus patient 517, p = 1.8310
 5; patient 461 versus patient 520, p = 1.1310
 3; patient
132 versus patient 422, p =63 10
 6; and patient 132 versus patient 476, p = 4.3 3 10
 4.
(E and F) RE analysis with heteroclitic peptides (E) M26 and (F) G209–2M. Weighted means were as follows: patient 517, 10.6; patient 520, 11.1;
patient 461, 11.2; patient 422, 10.5; patient 476, 11.6; and patient 132, 11.3.
DOI: 10.1371/journal.pmed.0010028.g005
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an important consideration in design of future vaccine
strategies.
Differential recognition of native and heteroclitic peptides
by many T cells may also account for the induction of non-
tumor-lytic clones by heteroclitic peptide vaccines, which has
been suggested previously [23,32]. However, our data suggest
that epitope density may be the dominant driving factor for
RE in vivo. In all of the vaccine-elicited T cell responses, many
of the T cells generated were either of low or intermediate RE
not only for the native peptide, but also for the heteroclitic
peptide, and exhibited no or intermediate lysis of tumor
targets. In contrast, nearly all of the clones generated from
the endogenous responses were of high RE. This suggests that
the high dosage of peptides administered in vaccinations and
the increased binding capacity of heteroclitic peptides to
MHC molecules—the very quality that provides them with
increased immunogenicity—drive the induction of many T
cells with low RE for both heteroclitic and native peptides.
Another implication of this study is that the number of
cells measured by current methods, including ELISPOT or
staining with MHC tetramers, may not correlate directly with
the RE or tumor reactivity of T cell responses to vaccination.
For example, of the nine clones analyzed from patient 517,
none were efﬁcient in tumor cell lysis, yet these cells were
detectable by MHC tetramer staining. T cells with low RE for
native TAA do not efﬁciently lyse tumor, and therefore are
unlikely to have an impact on clinical outcome. Furthermore,
it may be possible that low-RE TAA-speciﬁc T cells may
interfere with elicitation of high-RE T cells, either by direct
competition for antigen on APC surface [33,34] or down-
modulation of peptide–MHC complexes.
Our data support the notion that not only quantity, but
quality, of the T cell response elicited by vaccination may be
important for clinical efﬁcacy. There are a number of
strategies to increase the magnitude of T cell responses to
peptide vaccines. These include using various adjuvants, such
as incomplete Freund’s adjuvant and immunomodulatory
agents, such as IL-12 [4], GM-CSF [5], anti-CTLA-4 Abs [35],
or heat shock proteins [36]. Thus far, none of these
approaches have produced improved clinical outcomes. Our
data suggest that in addition to driving higher numbers of
vaccine-elicited T cells, strategies to modulate the relative RE
of T cell responses are also needed. While the selective
activation of high- versus low-RE T cells is relatively easy to
manipulate in vitro via stimulation with limiting amounts of
peptides, this may be more difﬁcult to control in vivo. It is
important to bear in mind that signals needed to drive a de
novo naı ¨ve T cell response may be different from those
required to drive further expansion of an activated T cell
population [37]. Thus, a complete vaccination strategy may
involve an initial induction phase, followed by progressive
shaping of the response to higher RE. Although heteroclitic
peptide vaccination may drive T cells of mixed high and low
RE, such a strong stimulus may be needed to induce an initial
de novo T cell response. Studies in mice suggest that once
activated, effector CD8þT cells may have an increase in RE of
up to 70-fold compared to naı ¨ve cells [38,39,40]. Thus, naı ¨ve
TAA-speciﬁc T cells, with inadequate RE to become activated
by low densities of native peptides present on tumor cells,
may become efﬁcient in tumor lysis upon vaccination with
heteroclitic peptide. This notion has support from studies in
tolerized mice: vaccination with a heteroclitic peptide analog
recruited T cells, which were responsive to secondary
stimulation with native peptide [41,42]. Therefore, optimized
use of heteroclitic peptide to induce an initial peptide-
speciﬁc T cell response, followed by selective expansion of the
highest RE tumor-lytic T cells may be needed for an effective
strategy with clear clinical application.
In summary, we have demonstrated that vaccination with
heteroclitic peptide at high concentrations may drive T cell
responses of variable tumor-cytolytic potential in cancer
patients—and that the ability to lyse tumor cells correlates
with the T cell’s RE for native peptides. This represents an
important—but not sole—factor in explaining the lack of
correlation between immunological and clinical responses
after vaccination for cancer. Importantly, the situation is
different in endogenous responses, in which cells are
predominantly of high RE. This suggests that the manner in
which T cells are elicited in vivo are different in these two
settings and may underlie their differences in biology.
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Patient Summary
Why Was This Study Done? Our immune system protects us against
infectious diseases. It can also recognize and destroy early cancer cells
before they form tumors. Researchers have been trying to find a way to
boost the anti-cancer function of the immune system so that it can kill
even established tumors. This is the idea behind developing vaccines for
treating cancer—the vaccine alerts and boosts the patient’s immune
system and so helps to fight the cancer. The idea of enlisting the
immune system against cancer has been around for a long time. There
have been some spectacular successes, but it has proven difficult to find
vaccines that work in more than just a few patients. And we don’t yet
understand why vaccines seem to work in some patients but not in
others.
What Did the Researchers Do? Peter Lee and colleagues are trying to
find out why some patients respond to vaccines and others don’t by
looking at the immune response in vaccinated patients. In this study,
using state-of-the art technology, they examined patients who received
different vaccines against the skin cancer melanoma. They concentrated
on the so-called killer T cells (cytotoxic T cells), which directly attack and
kill tumor cells, and analyzed them in great detail.
What Did They Find? Most cytotoxic T cells produced by patients after
vaccination—including vaccination with so-called heteroclitic peptides
that had been specifically designed to provoke a very strong immune
response—did not kill tumor cells very well, but a few of them did. These
results provide some explanation as to why cancer vaccines haven’t been
as successful as many had hoped, but also suggest that if it were
possible to get more of the potent T cells or to expand the ones that are
already produced with the current vaccines, there would be a stronger
anti-tumor response.
What Next? How to get effective cancer vaccines remains an open
question. But at least technologies such as those used in this study now
exist that allow researchers to analyze how the immune systems of
different patients react to vaccination and hence can guide the
development of better vaccines.
Additional Information. The Cancer Research Institute: http://
www.cancerresearch.org/
US Food and Drug Administration page on cancer vaccines: http://
www.cancerresearch.org/
University of Michigan page on cancer vaccines: http://www.cancer.
med.umich.edu/learn/cancervaccines.htm
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